Please login to the form below

Not currently logged in
Email:
Password:

GSK's Dr Brett Haumann takes up chief medical officer role at Circassia

Joins as UK biopharma prepares to move lead technology ToleroMune into phase III

Cirassia Dr Brett HaumannDr Brett Haumann has left GlaxoSmithKline to join UK-based biopharmaceutical company Circassia as its new chief medical officer.

The allergy specialist is currently preparing its lead product candidate for late-stage trials and said the addition of Dr Haumann's regulatory, medical and development expertise would prove invaluable.

He has over 15 years' experience of pharmaceutical development gained at Glaxo Wellcome and then GlaxoSmithKline, during which he held a number of positions of increasing seniority.

Most recently these saw him serve as VP and medicines development leader responsible for the late-stage development of once-daily inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD).

Prior to his time in the pharmaceutical industry, Dr Haumann practised internal medicine and conducted clinical research in South Africa.

Steve Harris, Circassia's CEO, said: “With his expertise in respiratory medicine, wide network of opinion leader contacts and proven track record in managing complex phase III studies, Brett is the ideal person to help Circassia drive its first product to market.

“We are confident our ToleroMune technology has the potential to revolutionise allergy treatment, and the leadership Brett has already demonstrated in managing one of GSK's most important development programmes will help Circassia make this ambitious goal a reality.”

ToleroMune uses small sections of allergens (epitopes) to generate regulatory T cells that suppress allergic responses and create immune tolerance in patients.

Circassia has so far successfully brought it through mid-stage trials with cat, house dust mite, ragweed and grass allergy therapies.

13th September 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics